Jazz Pharmaceuticals has enrolled the first patient in a Phase II clinical trial to assess the efficacy and safety of defibrotide for treatment of an acute graft-versus-host-disease (aGvHD) in adult and pediatric patients after allogeneic hematopoietic stem cell transplant (HSCT).

GvHD is a life-threatening complication of HSCT and is considered to be the most frequent cause of morbidity and non-relapse mortality following allogeneic HSCT.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The prospective, randomised, open-label study will be conducted across around 60 medical centres in the US, Canada, and European Union.

As part of the study, defibrotide will be added to standard of care immunoprophylaxis for the prevention of aGvHD, and will be compared to the standard of care alone.

Around 150 adult and pediatric patients who have undergone allogeneic HSCT from an unrelated donor are expected to be enrolled in the study.

“Despite the use of current immunoprophylaxis strategies, graft-versus-host disease remains a leading cause of non-relapse mortality after allogeneic stem cell transplant.”

The trial’s primary endpoint is cumulative incidence of Grade B-D aGvHD by day +100 post-allogeneic HSCT.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Jazz Pharmaceuticals chief medical officer Karen Smith said: said: “Potential complications of hematopoietic stem cell transplant such as acute graft-versus-host disease can be life-threatening and even fatal.

“Despite the use of current immunoprophylaxis strategies, graft-versus-host disease remains a leading cause of non-relapse mortality after allogeneic stem cell transplant.”

The Phase II trial complements Jazz’s ongoing Phase III clinical trial of defibrotide to treat hepatic veno-occlusive disease (VOD) in high-risk adult and pediatric patients undergoing hematopoietic stem cell transplant.

VOD is a rare complication of HSCT that occurs in nearly 9%-14% of HSCT patients.